Deciphera Pharmaceuticals Dirección
Dirección controles de criterios 3/4
El CEO de Deciphera Pharmaceuticals' es Steve Hoerter , nombrado en Mar 2019, tiene una permanencia de 5.08 años. compensación anual total es $3.55M, compuesta por 19.8% salario y 80.2% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.089% de las acciones de la empresa, por valor de $1.03M. La antigüedad media del equipo directivo y de la junta directiva es de 4.2 años y 8.8 años, respectivamente.
Información clave
Steve Hoerter
Chief Executive Officer (CEO)
US$6.0m
Compensación total
| Porcentaje del salario del CEO | 12.3% |
| Permanencia del CEO | 5.1yrs |
| Participación del CEO | 0.09% |
| Permanencia media de la dirección | 4.2yrs |
| Promedio de permanencia en la Junta Directiva | 8.8yrs |
Actualizaciones recientes de la dirección
Recent updates
Diving Into Deciphera Pharmaceuticals
Apr 26We Think Deciphera Pharmaceuticals (NASDAQ:DCPH) Can Afford To Drive Business Growth
Mar 13
We Think Deciphera Pharmaceuticals (NASDAQ:DCPH) Can Afford To Drive Business Growth
Dec 02Are Investors Undervaluing Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) By 41%?
Sep 25Deciphera Pharmaceuticals (NASDAQ:DCPH) Is In A Good Position To Deliver On Growth Plans
Jul 26Calculating The Intrinsic Value Of Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH)
Jun 22Lacklustre Performance Is Driving Deciphera Pharmaceuticals, Inc.'s (NASDAQ:DCPH) Low P/S
May 08We Think Deciphera Pharmaceuticals (NASDAQ:DCPH) Can Afford To Drive Business Growth
Apr 10We Think Deciphera Pharmaceuticals (NASDAQ:DCPH) Can Afford To Drive Business Growth
Dec 29Deciphera initiated at buy at Cowen on Qinlock growth, pipeline; sees 68% upside
Aug 29Deciphera Pharmaceuticals Q2 2022 Earnings Preview
Aug 03We Think Deciphera Pharmaceuticals (NASDAQ:DCPH) Needs To Drive Business Growth Carefully
Jul 29Deciphera Pharmaceuticals: Not Too Happy With The Risk-Reward Right Now
Feb 11Deciphera Pharmaceuticals: The 75% Haircut Doesn't Seem Justified
Nov 22Deciphera Pharmaceuticals (NASDAQ:DCPH) Is In A Good Position To Deliver On Growth Plans
Aug 26Deciphera Pharmaceuticals posts data from cancer studies at ASCO21
Jun 04Companies Like Deciphera Pharmaceuticals (NASDAQ:DCPH) Are In A Position To Invest In Growth
May 10Growth Investors: Industry Analysts Just Upgraded Their Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) Revenue Forecasts By 16%
Feb 11
Deciphera Pharmaceuticals (NASDAQ:DCPH) Is In A Good Position To Deliver On Growth Plans
Feb 05Deciphera to expand geographic reach and clinical potential of ripretinib
Jan 11Deciphera Pharmaceuticals, Inc.'s (NASDAQ:DCPH) Intrinsic Value Is Potentially 72% Above Its Share Price
Dec 15Deciphera completes enrollment in late-stage study of ripretinib in GIST patients
Nov 30Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Dec 31 2023 | US$6m | US$738k | -US$195m |
| Sep 30 2023 | n/a | n/a | -US$194m |
| Jun 30 2023 | n/a | n/a | -US$187m |
| Mar 31 2023 | n/a | n/a | -US$182m |
| Dec 31 2022 | US$4m | US$703k | -US$179m |
| Sep 30 2022 | n/a | n/a | -US$221m |
| Jun 30 2022 | n/a | n/a | -US$258m |
| Mar 31 2022 | n/a | n/a | -US$286m |
| Dec 31 2021 | US$9m | US$676k | -US$300m |
| Sep 30 2021 | n/a | n/a | -US$274m |
| Jun 30 2021 | n/a | n/a | -US$258m |
| Mar 31 2021 | n/a | n/a | -US$255m |
| Dec 31 2020 | US$8m | US$650k | -US$266m |
| Sep 30 2020 | n/a | n/a | -US$271m |
| Jun 30 2020 | n/a | n/a | -US$263m |
| Mar 31 2020 | n/a | n/a | -US$218m |
| Dec 31 2019 | US$9m | US$435k | -US$192m |
| Sep 30 2019 | n/a | n/a | -US$157m |
| Jun 30 2019 | n/a | n/a | -US$126m |
| Mar 31 2019 | n/a | n/a | -US$126m |
| Dec 31 2018 | US$447k | n/a | -US$100m |
Compensación vs. Mercado: La compensación total ($USD3.55M) de Steve está en línea con el promedio de empresas de tamaño similar en el mercado US ($USD3.44M).
Compensación vs. Ingresos: La compensación de Steve ha aumentado mientras la empresa no es rentable.
CEO
Steve Hoerter (52 yo)
5.1yrs
Permanencia
US$6,010,712
Compensación
Mr. Steven L. Hoerter, also known as Steve, serves as Director at ORIC Pharmaceuticals, Inc. since August 2021. He has been President and Chief Executive Officer of Deciphera Pharmaceuticals, Inc. since Ma...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| President | 5.1yrs | US$6.01m | 0.089% $ 1.1m | |
| Executive VP | 9.2yrs | US$2.03m | 0.052% $ 622.8k | |
| Executive VP & Chief Scientific Officer | less than a year | US$3.06m | 0% $ 0 | |
| Senior VP & Chief Commercial Officer | 5.6yrs | US$1.58m | 0.038% $ 459.3k | |
| Executive VP & Chief Medical Officer | 4.5yrs | US$2.13m | 0.088% $ 1.1m | |
| Senior VP & Chief Technical Officer | less than a year | sin datos | sin datos | |
| Senior Vice President of Finance & Investor Relations | no data | sin datos | sin datos | |
| Senior VP & General Counsel | 5.1yrs | sin datos | sin datos | |
| Senior VP & Chief Human Resources Officer | 2.3yrs | sin datos | sin datos | |
| Senior VP & Chief Development Officer | 4.2yrs | sin datos | 0.042% $ 502.1k | |
| Senior VP & Head of International | 3.2yrs | sin datos | sin datos | |
| Senior Vice President of Clinical Development | 3.3yrs | sin datos | sin datos |
4.2yrs
Permanencia media
52yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de DCPH se considera experimentado (4.2 años antigüedad media).
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| President | 5.9yrs | US$6.01m | 0.089% $ 1.1m | |
| Independent Director | 9.2yrs | US$388.59k | 0% $ 0 | |
| Independent Director | 7.5yrs | US$396.09k | 0% $ 0 | |
| Independent Director | 7.6yrs | US$398.55k | 0% $ 0 | |
| Independent Chairman | 4.3yrs | US$403.30k | 0% $ 0 | |
| Member of Scientific Advisory Board | 8.8yrs | sin datos | sin datos | |
| Independent Director | 16.7yrs | US$414.77k | 0% $ 0 | |
| Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Member of Scientific Advisory Board | 8.8yrs | sin datos | sin datos | |
| Member of Scientific Advisory Board | 8.8yrs | sin datos | sin datos | |
| Independent Director | 9.2yrs | US$386.05k | 0.013% $ 161.3k | |
| Member of Scientific Advisory Board | no data | sin datos | sin datos |
8.8yrs
Permanencia media
61yo
Promedio de edad
Junta con experiencia: La junta directiva de DCPH se considera experimentada (8.8 años de antigüedad promedio).